'+pages+''); $('.stream > div:odd').addClass('bgr_color'); updateHeight('#history'); }); window.activateTabArea = ensure(function(tab, areas){ var parsed = false; var parts = (areas || '').split('/'); window.fsonload = $.inArray('fs', parts) >= 0; if(fsonload){ parts.splice(parts.indexOf('fs'), 1); } var replayMode = false; if($.inArray('replay', parts)>=0){ replayMode = 'replay'; } var noSoundMode = false; if($.inArray('nosound', parts)>=0){ noSoundMode = 'nosound'; } if($.inArray('ns', parts)>=0){ noSoundMode = 'ns'; } var previewMode = null; if($.inArray('p', parts)>=0){ previewMode = 'p'; } if($.inArray('preview', parts)>=0){ previewMode = 'preview'; } if($.inArray('repeat', parts)>=0){ replayMode = 'repeat'; } if($.inArray('r', parts)>=0 || $.inArray('ro', parts)>=0){ replayMode = 'r'; } if(replayMode){ parts.splice(parts.indexOf(replayMode), 1); } if(noSoundMode){ parts.splice(parts.indexOf(noSoundMode), 1); } if(previewMode){ parts.splice(parts.indexOf(previewMode), 1); } if(previewMode){ if(!parts.length){ parts = ['1-14', '999:59']; } } var area = parts[0]; if(tab == 'history' && false){ var page = parseInt(area || '1') || 1; $.ajax({ url: 'https://login.wn.com/recent/json/?pp='+history_pp+'&skip='+history_pp*(page-1), dataType: 'jsonp', success: function(response){ $ensure(function(){ renderHistory(response, page); }); } }); return true; } if(tab == 'global_history' && false){ var page = parseInt(area || '1') || 1; globalHistory.fetchStream(page, '', function(){ updateHeight('#global_history'); }); return true; } if(tab == 'my_playlists' && false){ var page = parseInt(area || '1') || 1; myPlaylists.fetchStream(page, '', function(){ updateHeight('#my_playlists'); }); return true; } if(tab == 'my_videos' && false){ var page = parseInt(area || '1') || 1; myVideos.fetchStream(page, '', function(){ updateHeight('#my_videos'); }); return true; } if(tab == 'related_sites' && areas && matchPosition(areas)){ var seconds = parsePosition(areas); scrollRelated(seconds); return false; } if(matchPosition(area) || matchAction(area)){ parts.unshift('1'); area = parts[0]; } if(tab == 'expand' && area && area.match(/\d+/)) { var num = parseInt(area); if(num < 100){ //FIX ME. Load news page with ajax here } else if(num > 1900){ //FIX ME. Load timeline page with ajax here } } else if(tab.match(/^playlist\d+$/)){ var playerId = parseInt(tab.substring(8)); var vp = videoplayers[playerId]; window.descriptionsholder = $('.descriptionsplace'); if(!vp) return; // why? no player? if(replayMode){ $('.replaycurrent'+playerId).attr('checked', true); vp.setReplayCurrent(true); } var playQueue = []; window.playQueue = playQueue; var playQueuePosition = 0; var playShouldStart = null; var playShouldStop = null; var parseList = function(x){ var items = x.split(/;|,/g); var results = []; for (i in items){ try{ var action = parseAction(vp, items[i]); if(!action.video){ if(window.console && console.log) console.log("Warning: No video for queued entry: " + items[i]); }else{ results.push(action); } }catch(e){ if(window.console && console.log) console.log("Warning: Can''t parse queue entry: " + items[i]); } } return results; }; var scrollToPlaylistPosition = function(vp){ var ppos = vp.getPlaylistPosition(); var el = vp.playlistContainer.find('>li').eq(ppos); var par = el.closest('.playlist_scrollarea'); par.scrollTop(el.offset().top-par.height()/2); } var updateVolumeState = function(){ if(noSoundMode){ if(noSoundMode == 'turn-on'){ clog("Sound is on, vsid="+vp.vsid); vp.setVolumeUnMute(); noSoundMode = false; }else{ clog("Sound is off, vsid="+vp.vsid); vp.setVolumeMute(); noSoundMode = 'turn-on'; } } } var playQueueUpdate = function(){ var playPosition = playQueue[playQueuePosition]; vp.playFromPlaylist(playPosition.video); scrollToPlaylistPosition(vp); playShouldStart = playPosition.start; playShouldStop = playPosition.stop; }; var playQueueAdvancePosition = function(){ clog("Advancing play position..."); playQueuePosition ++; while(playQueuePosition < playQueue.length && !playQueue[playQueuePosition].video){ playQueuePosition ++; } if(playQueuePosition < playQueue.length){ playQueueUpdate(); }else if(vp.getReplayCurrent()){ playQueuePosition = 0; playQueueUpdate(); vp.seekTo(playShouldStart); vp.playVideo(); }else{ vp.pauseVideo(); playShouldStop = null; playShouldStart = null; } }; function loadMoreVideos(playerId, vp, start, finish, callback){ var playlistInfo = playlists[playerId-1]; if(playlistInfo.loading >= finish) return; playlistInfo.loading = finish; $.ajax({ url: '/api/upge/cheetah-photo-search/query_videos2', dataType: 'json', data: { query: playlistInfo.query, orderby: playlistInfo.orderby, start: start, count: finish-start }, success: function(response){ var pl = vp.getPlaylist().slice(0); pl.push.apply(pl, response); vp.setPlaylist(pl); callback(); } }); } if(parts.length == 1 && matchDash(parts[0])){ var pl = vp.getActualPlaylist(); var vids = parseDash(parts[0]); parts = []; for(var i = 0; i < vids.length; i++){ playQueue.push({ 'video': pl[vids[i]-1], 'start': 0, 'stop': null }) } if(vids.length){ if(vids[vids.length-1]-1>=pl.length){ loadMoreVideos(playerId, vp, pl.length, vids[vids.length-1], function(){ if(fsonload){ activateTabArea(tab, parts[0]+'/fs'); }else{ activateTabArea(tab, parts[0]); } var pls = vp.getPlaylist(); vp.playFromPlaylist(pls[pls.length-1]); vp.playVideo(); scrollToPlaylistPosition(vp); }); return true; } } if(playQueue){ playQueueUpdate(); vp.playVideo(); parsed = true; playShouldStart = 0; } } if(previewMode){ var vids = []; var dur = 0; var pl = vp.getActualPlaylist(); area = parts[0]; if(parts.length == 1 && matchPosition(parts[0])){ vids = parseDash('1-'+pl.length); dur = parsePosition(parts[0]); parts = []; }else if(parts.length == 1 && matchDash(parts[0])){ vids = parseDash(parts[0]); dur = parsePosition("999:59"); parts = []; } if(parts.length == 2 && matchDash(parts[0]) && matchPosition(parts[1])){ vids = parseDash(parts[0]); dur = parsePosition(parts[1]); parts = []; } for(var i = 0; i < vids.length; i++){ playQueue.push({ 'video': pl[vids[i]-1], 'start': 0, 'stop': dur }) } if(playQueue){ playQueueUpdate(); vp.playVideo(); parsed = true; } } if(parts.length>1){ for(var i = 0; i < parts.length; i++){ var sel = findMatchingVideo(vp, parts[i]); if(sel){ playQueue.push({ 'video': sel, 'start': 0, 'stop': null }) } } if(playQueue){ playQueueUpdate(); vp.playVideo(); parsed = true; } }else if(area){ var sel = findMatchingVideo(vp, area); if(sel){ vp.playFromPlaylist(sel); playShouldStart = 0; parsed = true; } } if(fsonload || replayMode){ playShouldStart = 0; } if(document.location.search.match('at=|queue=')){ var opts = document.location.search.replace(/^\?/,'').split(/&/g); for(var o in opts){ if(opts[o].match(/^at=(\d+:)?(\d+:)?\d+$/)){ playShouldStart = parsePosition(opts[o].substr(3)) } if(opts[o].match(/^queue=/)){ playQueue = parseList(opts[o].substr(6)); if(playQueue){ playQueuePosition = 0; playQueueUpdate(); } } } } if(matchPosition(parts[1])){ playShouldStart = parsePosition(parts[1]); parsed = true; } if(matchAction(parts[1])){ var action = parseAction(vp, area+'/'+parts[1]); playShouldStart = action.start; playShouldStop = action.stop; parsed = true; } if(playShouldStart !== null && !playQueue.length){ playQueue.push({ video: vp.getCurrentVideo(), start: playShouldStart, stop: playShouldStop }); } if(playShouldStart != null){ setInterval(function(){ if(playShouldStop && vp.currentPlayer && vp.currentPlayer.getCurrentTime() > playShouldStop){ playShouldStop = null; if(vp.getCurrentVideo() == playQueue[playQueuePosition].video){ playQueueAdvancePosition(); }else{ playShouldStart = null; } } }, 500); vp.playerContainer.bind('videoplayer.player.statechange', function(e, state){ if(state == 'ended'){ // advance to the next video playQueueAdvancePosition(); } }); vp.playerContainer.bind('videoplayer.player.readychange', function(e, state){ if(state){ updateVolumeState(); if(playShouldStart !== null){ vp.seekTo(playShouldStart); playShouldStart = null; }else{ playShouldStop = null; // someone started other video, stop playing from playQueue } } if(fsonload) { triggerFullscreen(playerId); fsonload = false; } }); } } else if(tab.match(/^wiki\d+$/)){ if(firstTimeActivate){ load_wiki($('#'+tab), function(){ if(area){ var areaNode = $('#'+area); if(areaNode.length>0){ $('html, body').scrollTop(areaNode.offset().top + 10); return true; } } }); } } return parsed; }) window.activateTab = ensure(function(tab, area){ window.activeArea = null; if(tab == 'import_videos'){ if(area){ import_videos(area); }else{ start_import(); } return true; } if(tab == 'chat'){ update_chat_position($('.chat').eq(0)); window.activeArea = 'chat'; jQuery('.tabtrigger').offscreentabs('activateTab', 'chat'); return true; } if(tab in rev_names){ tab = rev_names[tab]; } if(tab.match(':')){ return false; } var sup = $('ul li a[id=#'+tab+']'); if(sup && sup.length>0){ window.activeArea = area; sup.first().click(); if(!window.activateTabArea(tab, area)){ window.activeArea = null; } window.activeArea = null; return true; }else{ var have_tabs = $('#playlist_menu li').length; if(tab.match(/^playlists?\d+$/)){ var to_add = +tab.substring(8).replace(/^s/,'')-have_tabs; if(to_add>0 && have_tabs){ add_more_videos(to_add); return true; } } } return false; }); window.currentPath = ensure(function(){ return window.lastHistory.replace(basepath, '').split('?')[0]; }); window.main_tab = window.main_tab || 'videos'; window.addHistory = ensure(function(path){ if(window.console && console.log) console.log("Adding to history: "+path); if(window.history && history.replaceState && document.location.hostname.match(/^(youtube\.)?(\w{2,3}\.)?wn\.com$/)){ if(path == main_tab || path == main_tab+'/' || path == '' || path == '/') { path = basepath; } else if( path.match('^'+main_tab+'/') ){ path = basepath + '/' + path.replace(main_tab+'/', '').replace('--','/'); } else { path = basepath + '/' + path.replace('--','/'); } if(document.location.search){ path += document.location.search; } if(window.lastHistory) { history.pushState(null, null, path); } else if(window.lastHistory != path){ history.replaceState(null, null, path); window.lastHistory = path; } } else{ path = path.replace('--','/'); if(path == main_tab || path == main_tab+'/' || path == '' || path == '/') { path = ''; } if(window.lastHistory != '/'+path){ window.location.hash = path? '/'+path : ''; window.lastHistory = '/'+path; } } }); $('.tabtrigger li a').live('click', ensure(function() { var tab = $(this).attr('id'); if(tab.substring(0,1) == '#'){ var name = tab.substring(1); if(name in menu_names){ name = menu_names[name][0]; } realTab = rev_names[name]; $('#'+realTab).show(); if(window.console && console.log) console.log("Triggering tab: "+name+(window.activeArea?" activeArea="+window.activeArea:'')); var path = name; if(window.activeArea){ path = path + '/' + window.activeArea; } if(tab.match(/#playlist\d+/) || tab.match(/#details\d+/)){ $('.multiple-playlists').show(); $('.related_playlist').show(); $('.longest_videos_playlist').show(); }else { $('.multiple-playlists').hide(); $('.related_playlist').hide(); $('.longest_videos_playlist').hide(); } // start the related script only when the tab is on screen showing if (tab.match(/related_sites/)) { if (mc) { mc.startCredits(); } } window.activeTab = realTab; addHistory(path); setTimeout(ensure(function(){ if(tab.match(/language--/)){ $('.tabtrigger').offscreentabs('activateTab', 'language'); } if(tab.match(/weather/)) { $('.tabtrigger').offscreentabs('activateTab', 'weather'); loadContinent(); } updateMenus(tab); updateHeight(); }), 10); } return false; })); }); -->

'); } else { var query = elem.find('.keywords').html(); $.ajax({ context: elem, url: 'https://wn.com/api/upge/cheetah-search-adv/video', cache: true, data: { 'query': query }, dataType: 'jsonp', success: function(text) { if (text.length > 0) { video_id = text[0].id; elem.find('.player').html(''); } } }); } } var stopAllYouTubeVideos = function() { var iframes = document.querySelectorAll('iframe'); Array.prototype.forEach.call(iframes, function(iframe) { iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*'); }); } jQuery(function() { jQuery(".playVideo").live("click", function() { if(!$(this).hasClass("played")){ stopAllYouTubeVideos(); var elem = $(this); setTimeout(function(){ mouseOverMe(elem); }, 1000); } }); jQuery(".description_box .expandContent").live("click", function() { elem = $(this).parent().parent().parent().find('.descContent'); if(elem.height() > 51) { elem.css('height', '44px'); $(this).html('Show More '); }else{ elem.css('height', 'auto'); $(this).html('Hide '); } }); jQuery('.interview-play-off').click(function() { $(".interview-play-off").hide(); $(".interview-play").show(); $(".videoplayer-control-pause").click(); }); jQuery(".video-desc .show_author_videos").live("click", function() { query = $(this).attr('title'); container = $(this).parent().parent().parent().find('.video-author-thumbs'); $(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px'); jQuery.ajax({ url: '/api/upge/cheetah-photo-search/videoresults', data: {'query': query}, success: function(text) { if(!text) { text = i18n("No results"); } container.html(jQuery(text)); } }); }); }); // -->

Latest News for: adenosine a3 receptor

Edit

Liver Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

GetNews 23 Oct 2024
The study consists of two parts ... Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR) ... NV.
Edit

Hepatocellular Carcinoma Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

GetNews 20 Sep 2024
Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR).
Edit

Hepatic Tumor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024

GetNews 20 Sep 2024
It covers the pipeline drug profiles, including clinical and nonclinical stage products ... It further highlights the inactive pipeline products in this space ... Can Fite Biopharma. Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist ... ETN101.
Edit

Liver Cancer Pipeline 2024 | Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, ...

GetNews 09 Jul 2024
Liver Cancer Emerging Drugs Profile ... Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR).
Edit

Hepatic Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

GetNews 26 Jun 2024
... Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma ... Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist.
Edit

Liver Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

GetNews 08 May 2024
Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR).
Edit

Unveiling the Role of CD73: A Key Player in Immune Regulation and Beyond

Pharmiweb 17 Jan 2024
Notably, adenosine's influence also extends to the A2B receptor (ADORA2B), found on DCs and macrophages ... Further complexity arises as cancer cells also express the adenosine A1 receptor (ADORA1) and A3 receptor (ADORA3).
Edit

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Pharmiweb 04 Dec 2023
Study will aim to enroll about 20 patients to establish safety and clinical activity ... (NYSE American. CANF) (TASE ... Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR) ... .
Edit

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and ...

Hastings Tribune 24 Aug 2023
(NYSE American ... Dr ... Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with an excellent safety profile demonstrating evidence of efficacy in Phase II and Phase III clinical studies ... .
Edit

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

Pharmiweb 17 Jul 2023
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American. CANF) (TASE ... Fishman stated ... Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR) ... (NYSE American ... .
Edit

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

Pharmiweb 13 Jun 2023
Namodenoson’s robust effect reached 90% inhibition of pancreatic cancer growth in pre-clinical studies ... (NYSE American ... Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR) ... .
Edit

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

Pharmiweb 01 Jun 2023
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American. CANF) (TASE ... NAMODENOSON. Oncology ... During the first quarter, a study titled “Targeting the A3 adenosine receptor to treat hepatocellular carcinoma ... is 11% ... Liver Diseases ... Dr ... $ ... .
Edit

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

Pharmiweb 15 May 2023
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American. CANF) (TASE ... Dr ... Sari Fishman ... Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR) ... (NYSE American.
Edit

Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Pharmiweb 09 May 2023
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American. CANF) (TASE ... Pnina Fishman ... is 11% ... Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR) ... Contacts ... .
Edit

Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

Pharmiweb 02 May 2023
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American. CANF) (TASE ... Pnina Fishman ... is 11% ... Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR) ... Contacts ... .

Article Search

tools

Most Viewed

×
×
×
×

Loading...'); var query = jQuery('.radio_query').val(); jQuery.ajax({ data: { query: query }, url: '/api/upge/cheetah-photo-search/radio', success: function(text) { jQuery('.radio-search-results').html(jQuery(text)); updateHeight(); $('#RadioSearchTable').tablesorter(); $('#RadioSearchTable').trigger("update"); } }); return false; // do not submit the form }); $(".search-tools-btn").click(function () { header = $(this); content = $(".search-tools-content"); if(content.is(':visible')) { content.hide('slow'); header.html('Tools '); }else{ content.show('slow'); header.html('Hide '); } }); });